TYAN
2.6.2021 17:02:07 CEST | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, brings a variety of AI, cloud and storage server platforms incorporating the latest AMD EPYC™ 7003 Series processors in TYAN’s 2021 Server Solutions Online Exhibition beginning June 2nd .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005045/en/
“As the continued growth of using clouds for running HPC workloads, modern data center operators need to raise the bar for improved business outcomes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “With leadership performance and modern security features, TYAN’s 3rd Generation AMD EPYC processor-based platforms empower our customers to drive performance at a competitive price.”
Transport HX products deliver leadership compute in supercomputing and deep learning
Attendees will experience demonstrations on the latest AMD products and technologies in HPC, cloud, storage, and 5G halls at the 3D virtual environment. Leveraging 3rd Generation AMD EPYC processors, the Transport HX TN83-B8251 is a 2U dual-socket server with 16 DDR4-3200 DIMM slots, two half-height, half-length PCIe 4.0 x16 expansion slots for high-speed networking cards, and eight 3.5-inch SATA/NVMe U.2 hot-swap, tool-less drive bays. The platform supports up to four double-width GPU cards that can be easily scaled out to improve HPC and deep learning performance.
The Transport HX TS75A-B8252 is a 2U dual-socket server platform optimized for virtualization applications with support for 32 DDR4-3200/2933 DIMM slots and up to nine PCIe 4.0 x8 slots. The TS75A-B8252 accommodates 26 2.5-inch SATA hot-swap, tool-less drive bays with up to eight NVMe U.2 support by configuration. The Transport HX FT65T-B8030 is a 4U convertible tower server platform designed for cost-effective HPC applications. The system supports a single AMD EPYC 7003 Series processor, eight DDR4-3200 DIMM slots, eight 3.5-inch SATA, and two NVMe U.2 hot-swap, tool-less drive bays. The FT65T-B8030 supports four double-width PCIe 4.0 x16 slots for GPUs to accelerate HPC applications.
Transport CX lineup is designed for cloud and data analytics requiring large memory capacity
The Transport CX GC79-B8252 and Transport CX GC79A-B8252 are 1U dual-socket server platforms that are ideal for high-density data center deployment for a variety of memory-based computing applications. Both systems feature 32 DDR4-3200/2933 DIMM slots, two standard PCIe 4.0 x16 expansion slots, and an OCP 3.0 LAN mezzanine slot. The GC79-B8252 platform provides four 3.5-inch SATA and four 2.5-inch NVMe U.2 hot-swap, tool-less drive bays, while the GC79A-B8252 platform offers twelve 2.5-inch drive bays with up to twelve NVMe U.2 support.
The Transport CX GC68-B8036-LE and Transport CX GC68A-B8036 are cost-optimized single-socket cache server platforms featuring 16 DDR4-3200/2933 DIMMs, a pair of PCIe 4.0 x16 expansion slots and an OCP 2.0 LAN mezzanine slot in a 1U chassis. The GC68-B8036-LE accommodates four 3.5-inch SATA hot-swap, tool-less drive bays for large storage capacity and four 2.5-inch hot-swap, tool-less NVMe U.2 bays for application cache usage; the GC68A-B8036 offers twelve 2.5-inch hot-swap, tool-less drive bays with support for up to twelve NVMe U.2 devices for applications for high storage performance requirements.
The Transport CX TN73-B8037-X4S is a 2U multi-node server platform with four front-serviced compute nodes. Each node supports one AMD EPYC 7003 Series processor, four 2.5-inch hot-swap, tool-less NVMe/SATA drive bays, eight DDR4-3200 DIMM slots, three internal cooling fans, two standard PCIe 4.0 x16 expansion slots, two internal NVMe M.2 slots and one OCP 2.0 LAN mezzanine slot. The platform is suited for high-density data center deployments and targets scale-out applications with large numbers of nodes.
Transport SX lineup to deliver massive I/O and memory bandwidth for storage applications
The Transport SX TS65-B8253 is a 2U dual-socket hybrid software storage server for various datacenter and enterprise deployments supporting 16 DDR4-3200 DIMM slots and seven standard PCIe 4.0 slots. The platform offers twelve front 3.5-inch hot-swap, tool-less SATA drive bays with support for up to four U.2 NVMe SSDs, and two rear 2.5-inch hot-swap, tool-less SATA drive bays for boot drive deployment.
TYAN’s Transport SX TS65-S8036 and Transport SX TS65A-S8036 are 2U single-socket storage servers with support for 16 DDR4-3200/2933 DIMM slots, five PCIe 4.0 and one OCP 2.0 LAN mezzanine slots. The TS65-S8036 accommodates twelve front 3.5-inch and two rear 2.5-inch hot-swap, tool-less SATA drive bays for cloud storage applications, up to four NVMe U.2 devices are supported on the front twelve drive bays; the TS65A-S8036 offers 26 front and two rear 2.5-inch hot-swap, tool-less drive bays for high-performance data streaming applications, the 26 front drive bays can support up to 24 NVMe U.2 devices by configuration.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release
The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying
OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with
New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release
ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro
Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release
Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release
This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
